Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNDN .. spiked from 4 to 25 in a 3 days period ... in March 2007! ... the spike was caused by the following news:
A Food and Drug Administration advisory panel debated the findings but ultimately voted 13-4 that Dendreon had provided "substantial evidence" the product worked.
so .. all PPHMers ... comparing PPHM to DNDN ... if ... that's what they are waiting for ... ... would probably need to wait another 3-4 years (expected Sunrise Completion date: Dec16)
I do believe in PPHM platform ... BUT... the fact that
1. PPHM has publicly stated its interest in finding a Partner for the Phase 3 study ...
and
2. No partner has been announced ...
... makes me think that ... Bio-Pro ... MIGHT not be as bullish as Retail Investors on the Ihub board ... with respect to BAVI and its Potential.
EYE ... are you sure you are using the term Purchase correctly?
Take for Example the following transaction (you cited):
May 8, 2013 Date of Earliest Transaction (5/06/2013) 100,000 Shares at $1.41 This option vests in eight (8) equal quarterly installments over a two (2) year period beginning August 6, 2013 and each quarter thereafter until fully-vested.
As you can see, the Transaction Code is A (acquisition) and not P (purchase)
How much did Mr. Masten pay for the Options? --> $0.00
See: 8. Price of Derivative Security (Instr. 5)
So, Masten got the options for for free (as part of the incentive/compensation package), he did not pay for them. He did not Purchase them, he only acquired them. There is a huge difference between A and P.
Hopefully ... it was an honest mistake on your side.
are simply spam messages ... containing key words! ... It is pretty common! ... If you ask a chinese native speaker to translate the text to you ... he will revert back and say ... the text makes no sense ... and also add ... that's a pretty common spam technique in China.
October 2 short covering that must be reported by Friday?
What do you mean? .. we already know the short position ... as of Jan 15 2014 ... it was 8.852918m shares ... up form 8.478508m short interest reported for the period ending Jan 31, 2013.
so ... what should be reported ... with respect to Oct 2 ?
Many people here are mentioning a liver study ... whose results should be announced soon?
is the study you are talking about the following one:
"A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma"
If that's the study you are talking about, could you please tell me why you expect the results to be announced soon? Probably nothing to be heard before 2016. Look at the DL table:
Estimated Enrollment: 56 Study Start Date: November 2010 Estimated Study Completion Date: December 2015 Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Actually I am having an hard time ... figuring out why PPHM has decided to raise such an amount of money (98m of Preferred Shares + 27m under the ATM)
We do know that PPHM started a PIII trial for sunrise last December. This Trial will enroll 600 patients.
The average Phase 3 per-patient cost of $74,800 is higher than the Phase 1 and Phase 2 trials examined in this study. Furthermore, three Phase 3 trials surpassed $100,000 in per-patient costs — more than almost every Phase 1 or Phase 2 trial that we studied
Even if you take tha Upper range (100,000 USD per patient), the Cost for Sunrise Phase III would probably be not higher than 60m USD.
Recent developments put PPHM cash position at approximately (inclusind cash on hand as of October 2013) at 169m USD
Recent Cash Burn Rate ... was just below 4m USD per quarter.
Over the next 3 years PPHM could therefore have been expected to burn approximately 50m USD (rounded 3y*4q*4m/q)
If you add the 60m USD PPHM is probably going to spend for the Sunrise Phase III ... you will get to a cash need of 110m USD till the end of 2017.
So, why did PPHM need to raise 125m USD and bring its cash position to 169m USD?
I see 3 possible Explanations:
1. They might also start the other PIII clinical trial on their own
2. The Preferred Offering could be a way to let a partner in
3. The Preferred Offering could not be of 100m USD
Notes to point 3. The registration S3 was for 100m USD.This However does not mean they will raise the entire amount of money (100m USD). It could be that they issue Preferred for a nominal value of 50M USD. In the prospectus they did not indicate the amount to be issued).
PPHM SHARES getting weaker ... as the day progresses
already -6.55% ... at 1.57
Obviously investors did not like yesterday's announcement. I do still believe that PPHM and the Book Runner ... will structure the deal in a way that caused a POP ... in PPS.
Over the long run ... everything will come down to PPHM's pipeline.
The only way to validate PPHM's pipeline future potential (in the eyes of investors) ... would be ... to partner with a big Pharma firm.
the holder can choose to convert the Series E preferred into PPHM Common stocks:
"he Series E Preferred Stock has no stated maturity, is not subject to any sinking fund or mandatory redemption, and will remain outstanding indefinitely unless we repurchase, redeem or convert it into our common stock in connection with a Change of Control or a Market Trigger (as defined herein), or unless a holder chooses to convert the Series E Preferred Stock into our common stock. "
Let me start by saying that I have a long Position in PPHM. However, it seems to me .. that most of the posters on this board are failing to take into account the huge dilution this company has experienced over the past 10 years!
JUL1999 ... only 15m shares were outstanding Today ... more than 160m shares are outstanding!
The highest valuation (if we exclude the 2000 bubble) was reached in september 2012 ... at $509m ... ... which represent a current price of $3.17 ... when accounted for dilution (55m shares have been issued since September 2012)